1. Home
  2. SD vs VOGX Comparison

SD vs VOGX Comparison

Compare SD & VOGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SandRidge Energy Inc.

SD

SandRidge Energy Inc.

HOLD

Current Price

$14.63

Market Cap

502.8M

Sector

Energy

ML Signal

HOLD

Logo Vogenx Inc Common Stock

VOGX

Vogenx Inc Common Stock

N/A

Current Price

$32.71

Market Cap

475.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SD
VOGX
Founded
2006
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
502.8M
475.4M
IPO Year
2006
2026

Fundamental Metrics

Financial Performance
Metric
SD
VOGX
Price
$14.63
$32.71
Analyst Decision
Strong Sell
Analyst Count
1
0
Target Price
$15.00
N/A
AVG Volume (30 Days)
251.6K
210.1K
Earning Date
05-05-2026
N/A
Dividend Yield
3.07%
N/A
EPS Growth
12.43
N/A
EPS
1.22
N/A
Revenue
N/A
N/A
Revenue This Year
$12.65
N/A
Revenue Next Year
$1.75
N/A
P/E Ratio
$12.05
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.10
$14.80
52 Week High
$18.45
$35.50

Technical Indicators

Market Signals
Indicator
SD
VOGX
Relative Strength Index (RSI) 60.98 78.35
Support Level $14.37 $27.37
Resistance Level $15.71 $35.06
Average True Range (ATR) 0.33 4.36
MACD 0.05 -0.42
Stochastic Oscillator 71.14 52.68

Price Performance

Historical Comparison
SD
VOGX

About SD SandRidge Energy Inc.

SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. The company's primary areas of operation are the Mid-Continent in Oklahoma and Kansas.

About VOGX Vogenx Inc Common Stock

Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.

Share on Social Networks: